Lajos Pusztai

Nov 6, 2024 | cell.com | Michael Campbell |Denise Wolf |Christina Yau |Lamorna Brown-Swigart |Isela R. Gallagher |Zelos Zhu | +20 more

ResultsA total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).

Oct 2, 2024 | digitalcommons.library.tmc.edu | Jennifer K. Litton |Meredith M. Regan |Lajos Pusztai |Hope Rugo

PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points.

Sep 14, 2024 | nature.com | Katia Khoury |Hope Rugo |Rita Nanda |Alexandra Zimmer |Judy Boughey |Christos Vaklavas | +11 more

AbstractAmong the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes. Here we tested datopotamab–deruxtecan (Dato-DXd) in the I-SPY2.2 trial for patients with high-risk stage 2/3 breast cancer.

Jul 19, 2024 | onclive.com | Lajos Pusztai

Lajos Pusztai, MD, DPhil, professor of medicine, Yale School of Medicine, scientific co-director, Breast Center, co-director, Cancer Center Genomics, Genetics, and Epigenetics Program, Yale Cancer Center, and chair, Breast Cancer Research Committee of the South West Oncology Group, discusses the progress and challenges in monitoring molecular residual disease (MRD) in early breast cancer.

Dec 15, 2023 | onclive.com | Lajos Pusztai

Lajos Pusztai, MD, DPhil, professor of medicine, Medical Oncology, co-leader, Genetics, Genomics and Epigenetics, Yale Cancer Center, discusses the phase 2 DARE trial (NCT04567420) evaluating circulating tumor DNA (ctDNA)-guided second-line adjuvant therapy for patients with high-risk, stage II-III, estrogen receptor (ER)-positive, HER2-negative breast cancer, highlighting the importance of researching ctDNA utility in this patient population.